clinical trial · NCT06598943
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company·phase2·recruiting·n = 140
Ulcerative ColitisUlcerative Colitis ChronicEltrekibartMirikizumabPlacebo
brief summary
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
started
Oct 10, 2024
primary completion
Dec 1, 2027
completion
Sep 1, 2028
last updated
Apr 20, 2026
detailed description
The study will last approximately 4-5 years. Screening is required within 35 days prior to enrollment. For each participant, the total duration of the clinical trial will be about 69 weeks including screening.
official title
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol